PPARD and prostate carcinoma: Activation of PPARβ/δ by an agonist ligand canresult in increased proliferation of breast and prostate cancer cell lines, aswell as endothelial cells, and supports the hypothesis that PPARβ/δ antagonists might be oftherapeutic value in the management of common epithelial cancers [53].